Congresses

 

The below Genentech/Roche-sponsored congress posters and oral presentations include data presented at scientific meetings from mid-2019 onwards. Click the below links for congress publications of interest.

Low immunogenicity of emicizumab in persons with haemophilia A

Schmitt C, Emrich T, Asikanius E, et al. Poster presentation ABS141.

Safety and efficacy of emicizumab in persons with haemophilia A with/without FVIII inhibitors: Pooled data from four phase III studies (HAVEN 1–4)

Callaghan MU, Négrier C, Paz-Priel I, et al. Poster presentation ABS192.

Evaluating the economic burden associated with problem joints, across moderate and severe haemophilia A, in children and adults: CHESS Paediatrics and CHESS II

Chowdary P, Hermans C, Asghar S, et al. Poster presentation ABS1148.

An early view analysis of characteristics of persons with hemophilia Atreated with emicizumab using secondary claims data

Mahajerin A, Yang E, Patel AM, et al. Poster presentation.

Changes in healthcare resource use and costs after emicizumab initiation for hemophilia A

Mahajerin A, Khairnar R, Meyer CS, et al. Poster presentation.

Complications associated with central venous acceess devices in patients with hemophilia A: a secondary claims-base analysis

Orji C, Khairnar R, Patel AM, et al. Poster Presentation.

Summary of thromboembolic (TE) or thrombotic microangiopathy (TMA) events in persons taking emicizumab

Lee L, Moreno K, Kuebler P, et al. Oral presentation P131.

Final analysis of the STASEY trial: a single-arm, multicenter, open-label, Phase III clinical trial evaluating the safety and tolerability of emicizumab prophylaxis in persons with hemophilia A with factor VIII inhibitors

Jiménez-Yuste V, Peyvandi F, Klamroth R, et al. ISTH 2021; Poster presentation PB0521.

Bone and joint health markers in persons with hemophilia A treated with emicizumab in HAVEN 3

Kiialainen A, Niggli M, Kempton C, et al. Oral presentation.

Real-world treatment patterns, health outcomes, and healthcare resource use among persons with hemophilia A

Caplan EO, Patel AM, DeClue R, et al. Poster presentation 15.

An insight into clinical outcomes in mild, moderate, and severe hemophilia A (HA): A preliminary analysis of the CHESS II study

Nissen F, Burke T, Asghar S, et al. Oral presentation OC 09.3.

Effect of moderate and severe hemophilia A on daily life in children and their caregivers: A CHESS Paediatrics Study analysis

Khair K, Nissen F, Silkey M, et al. Oral presentation 147.

Surgical experience from four phase III studies (HAVEN 1–4) of emicizumab in persons with haemophilia A (PwHA) with or without FVIII inhibitors

Santagostino E, Oldenburg J, Chang T, et al. Oral presentation OC 60.1.

Patient access to hemophilia A treatment varies across US commercial health plans

Margaretos NM, Patel AM, Pranzer AD, et al. Poster presentation.

Timing of treated spontaneous bleeding in persons with haemophilia A receiving emicizumab prophylaxis 6 mg/kg once every 4 weeks

Pipe SW, Ko RH, Chang T, et al. Poster presentation P191.

Association of physical activity with bleeding frequency in children with hemophilia A: a CHESS PAEDs study analysis

Ofori-Asenso R, Nissen F, Silkey M, et al. ISTH 2021; Poster presentation PB0512.

Estimating the risk of myocardial infarction in persons with hemophilia A using a machine-learning approach with US claims data

Faghmous I, Flores C, Sarouei K, et al. Poster presentation P-1133.

Surgical experience from the Phase III STASEY trial of emicizumab prophylaxis in persons with haemophilia A (PwHA) with FVIII inhibitors: Data from the second interim analysis

Castaman G, Kremer Hovinga JA, Schutgens R, et al. Poster presentation PB0939.

An analysis of fatalities in persons with congenital hemophilia A reported in the FDA Adverse Event Reporting System (FAERS) database

De Ford C, Kuebler P, Shang A, et al. Poster presentation 25.

Real-world persistence with and adherence to emicizumab prophylaxis in persons with hemophilia A: a secondary claims database analysis

Mahajerin A, Khairnar R, Meyer CS, et al. Poster presentation 866.

Emicizumab treatment is efficacious and well tolerated long term in persons with haemophilia (PwHA) with or without FVIII inhibitors: Pooled data from four HAVEN studies

Callaghan M, Negrier C, Paz-Priel I, et al. Oral presentation OC 60.2.

A survey study of hematologists in the United States to understand disease management of patients with hemophilia A treated with emicizumab

Owens WE, Patel AM, Poulos K, et al. Poster presentation P205.

Emicizumab in obese adults with hemophilia A - pooled data from three Phase III studies (HAVEN 1, 3 and 4)

Recht M, Mahlangu J, Minhas M, et al. ISTH 2021; Poster presentation PB0435.

Factor VIII use in the treatment of breakthrough bleeds in hemophilia A patients without inhibitors on emicizumab prophylaxis: the phase 3 HAVEN 3 study experience

Callaghan M, Trzaskoma B, Ko RH, et al. Poster presentation P-2395.

A contemporary framework for understanding mortality in people with congenital hemophilia A (PwcHA)

Pipe SW, Kruse-Jarres R, Mahlangu JN, et al. Poster presentation 23.

Pharmacokinetics and coagulation biomarkers in persons with hemophilia A (PwHA) and FVIII inhibitors receiving emicizumab in the Phase IIIb STASEY study

Kiialainen A, Petry C, Jiménez-Yuste V, et al. Poster presentation PB0942.

A phase IV, multicenter, open-label study of emicizumab prophylaxis in persons with hemophilia A with or without FVIII inhibitors undergoing minor surgical procedures

Escobar M, Dunn A, Quon D, et al. Poster presentation 1786.

A single-arm, multicentre, open-label, phase III clinical trial to evaluate the safety and tolerability of prophylactic emicizumab in persons with haemophilia A (PwHA) with FVIII inhibitors (STASEY): Interim analysis results

Jiménez-Yuste V, Klamroth R, Castaman G, et al. Oral presentation OC 60.3.

Estimating the burden of intracranial hemorrhage in persons with hemophilia A using administrative claims data.

Mahajerin A, Patel AM, Yang E, et al. Poster presentation P-2398.

Associations between physical activity levels and bleeding frequency in people with mild, moderate, and severe hemophilia A (HA): A preliminary analysis of the CHESS II study

Nissen F, Burke T, Asghar S, et al. Poster presentation PB0943.

Characteristics of persons with hemophilia A treated with emicizumab with or without factor VIII inhibitors

Mahajerin A, Yang E, Patel AM, et al. Poster presentation 31.

Analysis of hemophilia A outcomes and treatment patterns using real-world data from the Canadian Hemophilia Bleeding Disorder Registry

Lee A, Germini F, Poon M, et al. Poster presentation 1793.

Joint bleeds in paediatric patients with haemophilia A: A CHESS study analysis

Castro FA, Silkey M, Khair K, et al. Oral presenation OC 70.1.

A systematic review of mortality statistics and causes of death in people with congenital hemophilia A (PwcHA)

Hay CR, Nissen F, Pipe SW. Poster presentation 32.

Long-term safety and efficacy for up to >5 years in a phase 1/2 study in patients with severe hemophilia A

Shima A, Nagao A, Taki M, et al. Poster presentation PB0950.

Safety and efficacy of emicizumab in persons with hemophilia A with or without FVIII inhibitors: pooled data from four phase III studies (HAVEN 1–4)

Callaghan MU, Négrier C, Paz-Priel I, et al. Poster presentation 1800.

Analytical performance evaluation of a dedicated calibrator and controls for emicizumab quantification

Ramamurthy N, Kucharski C, McInerney M, et al. Oral presentation OC 07.4.

Summary of thrombotic events or thrombotic microangiopathy events in persons taking emicizumab

Lee L, Moreno K, Kuebler P, et al. Poster presentation 35.

A randomized, multicenter, open-label, Phase III clinical trial to evaluate the efficacy, safety, and pharmacokinetics of prophylactic emicizumab versus no prophylaxis in persons with hemophilia A in the Asia-Pacific region (HAVEN 5)

Wang S, Zhao X, Wang X, et al. Poster presentation PB0957.

Problem joints and their clinical and humanistic burden in children and adults with moderate and severe hemophilia A: CHESS Paediatrics and CHESS II

McLaughlin P, Hermans C, Asghar S, et al. Poster presentation 2532.

Early patient experiences with emicizumab in the United States: a qualitative study

Markowitz JT, Patel AM, Raimundo K, et al. Poster presentation PB0244.

Second interim analysis results from the STASEY trial: A single-arm, multicenter, open-label, phase III clinical trial to evaluate the safety and tolerability of emicizumab prophylaxis in people with hemophilia A (PwHA) with FVIII inhibitors.

Jiménez-Yuste V, Klamroth R, Castaman G, et al. Poster presentation PB0958.

Bone and joint health markers in persons with hemophilia A (PwHA) treated with emicizumab in the HAVEN 3 clinical trial

Kiialainen A, Niggli M, Kempton C, et al. Poster presentation 36.

Real-world safety of emicizumab: The first interim analysis of the European Haemophilia Safety Surveillance (EUHASS) Database

Shang A, Bienz NS, Gadiraju R, et al. Poster presentation 2685.

Evaluating patient and caregiver treatment preferences in hemophilia A using a discrete choice experiment

Benton M, Shi L, Patel AM, et al. Poster presentation PB0245.

An insight into the impact of hemophilia A on daily life according to disease severity: A preliminary analysis of the CHESS II study

Noone D, Nissen F, Xu T, et al. Poster presentation 3449.

Health-related quality of life in paediatric patients with haemophilia A

Castro FA, Silkey M, Khair K, et al. Poster presentation PB0250.

Impact of hemophilia A inhibitor on joint health and health-related quality of life from the Hemophilia Utilization Group Studies Part VIII in the US

Ullmann MM, Manco-Johnson MJ, Roberts JC, et al. Poster presentation 3457.

Exposure–response modeling of emicizumab for the prophylaxis of bleeding in haemophilia A patients with and without inhibitors against factor VIII

Jonsson F, Schmitt C, Petry C, et al. Poster presentation PB0325.

Timing of treated spontaneous bleeding in persons with haemophilia A (PwHA) in the HAVEN 3 study

Mahlangu J, Oldenburg J, O'Connell N, et al. Poster presentation PB0694.

Emicizumab prophylaxis improves long-term physical health scores in persons with haemophilia A (PwHA) with and without inhibitors: update from the HAVEN 3 and HAVEN 4 studies

Skinner M, Negrier C, Paz-Priel I, et al. Poster presentation PB0698.

Treatment patterns and outcomes in persons with hemophilia A (PwHA): Analysis from the CHOICE survey in the United States

Patel AM, Cyhaniuk A, Raimundo K, et al. Poster presentation PB1404.

Emicizumab pediatric experience in clinical studies and beyond

Levy G. Oral Presentation.

Factor VIII use in the treatment of breakthrough bleeds in persons with hemophilia A without inhibitors on emicizumab prophylaxis: The phase III HAVEN 3 study experience

Callaghan M, Trzaskoma B, Ko RH, et al. Poster presentation.

Early patient experiences with emicizumab in the United States: a qualitative study

Markowitz JT, Patel AM, Raimundo K, et al. Poster presentation.